Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.94 +0.08 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
News headline image
MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis ↗
MacroGenics Inc (NASDAQ: MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a head-to-head matchup with breast... 
Via Benzinga
News headline image
Why Adaptimmune Therapeutics Stock Is Bolting Higher Today ↗
A major licensing deal with cancer giant Roche is pushing the biotech's shares higher this morning. 
Via The Motley Fool
News headline image
Adaptimmune Stock Moves Higher On Cancer Deal With Genentech ↗
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC:... 
Via Benzinga
News headline image
Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy ↗
Privately-held NeuExcell Therapeutics has collaborated with Spark Therapeutics to develop a treatment for Huntington's Disease (HD). Spark... 
Via Benzinga
News headline image
Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers
From Genentech
Via Business Wire
News headline image
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates ↗
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
News headline image
Why A Roche-Partnered Alzheimer's Drug Sent AC Immune Stock Flying ↗
AC Immune said Tuesday its drug slowed cognitive decline in Alzheimer's patients in a test, and ACIU stock rocketed to a six-month high. 
Via Investor's Business Daily
News headline image
See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate ↗
AC Immune SA (NASDAQ: ACIU) and its collaborating partner Genentech, part of Roche Holdings AG (OTC: RHHBY), have announced topline data from Phase... 
Via Benzinga
News headline image
After Bladder Cancer, Roche Pulls Breast Cancer Indication For Tecentriq In US ↗
Following a consultation from the FDA, Roche Holdings AG (OTC: RHHBY) has decided to withdraw its immunotherapy, Tecentriq (atezolizumab), to treat a type of... 
Via Benzinga
News headline image
Genentech Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
From Genentech
Via Business Wire
News headline image
Shape Therapeutics, Roche Form $3B RNA Editing Collaboration ↗
Shape Therapeutics Inc announced a multi-target strategic collaboration and license agreement with Roche Holding AG (OTC: RHHBY) for RNA editing technology.... 
Via Benzinga
News headline image
UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail ↗
The U.K. drug regulator has approved an antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holding AG (OTC: RHHBY) to prevent... 
Via Benzinga
News headline image
Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage ↗
Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization for critically ill COVID-19 patients after... 
Via Benzinga
News headline image
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer ↗
AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3... 
Via Benzinga
News headline image
Genentech's Polivy Plus R-CHP Shows Prolonged Survival In Newly Diagnosed DLBCL Patients ↗
Genentech, a member of Roche Holdings AG (OTC: RHHBY), announced that the pivotal Phase 3 POLARIX trial met its primary endpoint in people with previously... 
Via Benzinga
News headline image
Phase III Study Shows Genentech's Polivy Plus R-CHP Is the First Regimen in 20 Years to Significantly Improve Outcomes in Previously Untreated Aggressive Form of Lymphoma Compared to Standard of Care
From Genentech
Via Business Wire
News headline image
These OTC Securities Had the Most Trading Activity in July ↗
Photo by Federico Beccari on Unsplash In July, O... 
Via Benzinga
News headline image
Moderna Vs. BioNTech: How Do These High-Flying COVID-19 Vaccine Stocks Compare? ↗
Moderna, Inc. (NASDAQ: MRNA) and BioNTech SE (NASDAQ: BNTX) shares have been on tear ever since these companies embarked on their respective COVID-19 vaccine programs. Shares of... 
Via Benzinga
News headline image
Billionaire Masayoshi Son's SoftBank Claims $5B Stake In Roche: Bloomberg ↗
SoftBank Group Corp (OTC: SFTBF) has quietly acquired a $5 billion stake in Roche Holdings AG (OTC: RHHBF), making it one of the largest investors of the Roche,... 
Via Benzinga
News headline image
Outlook Therapeutics Stock Surges Positive ONS-5010 Data In Wet AMD Patients ↗
Outlook Therapeutics Inc (NASDAQ: OTLK) stock is trading higher in premarket session in reaction to positive top-line results from Phase 3 NORSE TWO trial... 
Via Benzinga
News headline image
Roche's Tecentriq As Adjuvant Treatment Under Priority Review With FDA For Early Lung Cancer ↗
The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) Tecentriq (atezolizumab), as adjuvant treatment for... 
Via Benzinga
News headline image
FDA Grants Priority Review to Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer
From Genentech
Via Business Wire
News headline image
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
News headline image
Know When To Hold 'Em, Know When To Fold 'Em ... ↗
A long Monday list identifying some sensible and some impenetrable moves behind today's market in our stocks. 
Via Talk Markets
News headline image
FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis ↗
Following the June update that 
Via Benzinga
News headline image
How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market ↗
Venclexta's potential indication for the treatment of myelodysplastic syndrome could mean billions for AbbVie this decade. 
Via The Motley Fool
News headline image
Roche's Faricimab US Application For Ocular Diseases Under Priority Review ↗
The FDA has accepted Roche Holding AG's (OTC: RHHBY) Biologics License Application seeking approval for faricimab in neovascular of wet age-related macular... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
From Genentech
Via Business Wire
News headline image
Data for Genentech’s Evrysdi (risdiplam) Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.